直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

Federal Circuit Affirms Principle of Party Presentation Allows the Parties, Not the Court, to Chart the Course of a Litigation

October 9, 2024

Authored and Edited by Emma N. Ng; Christina Ji-Hye Yang; Erik R. Puknys

In Astellas Pharma, Inc. v. Sandoz Inc., No. 23-2032 (Fed. Cir. Sept. 18, 2024), the Federal Circuit vacated the district court’s judgment and remanded the case.

Astellas’s ’780 patent relates to a sustained release formulation for the drug mirabegron. Following a bench trial, which was limited to infringement and validity under 35 U.S.C. § 112, the district court held sua sponte that the ’780 patent was invalid as directed to patent-ineligible subject matter under 35 U.S.C. § 101.

The Federal Circuit held the district court erred by disregarding the principle of party presentation and abused its discretion because patent eligibility was not raised below by Sandoz. The Federal Circuit stated that “[i]t is for the parties—not the court—to chart the course of litigation.” While Sandoz argued during oral argument that it pleaded an invalidity defense under § 101 in its answer, the Federal Circuit noted this argument was not raised on appeal and was thus forfeited.

The Federal Circuit declined to grant reassignment to a different judge on remand. The Federal Circuit was not convinced that the presiding judge could not resolve the outstanding issues impartially and fairly, particularly since the Federal Circuit clarified the “proper course for adjudication” on remand.

Tags

patentable subject matter, 35 U.S.C. § 101

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Global IP Enforcement, Litigation, and Trials

Branded Hatch-Waxman (ANDA) Litigation and Trials

Related Industries

Life Sciences

Pharmaceutical

Related Offices

Palo Alto, CA

Washington, DC

Contacts

Emma N. Ng
Associate
Washington, DC
+1 202 408 4149
Email
Christina Ji-Hye Yang
Partner
Washington, DC
+1 202 408 4465
Email
Erik R. Puknys
Partner
Palo Alto, CA
+1 650 849 6644
Email

Related Insights

Conference

2027 ABA-IPL Section Annual Meeting – IPLSPRING

April 14-15, 2027

Arlington

Conference

Patent Litigation Europe 2027

January 18-20, 2027

Amsterdam

Reception

2026 IPO Education Foundation Awards Dinner

December 15, 2026

Washington, DC

Conference

IP Life Sciences Forum 2026

December 13-15, 2026

Coral Gables

Panel Discussion

2026 Advanced Patent Law Institute

December 3-4, 2026

Stanford

Webinar

Data and Market Exclusivity: An Update on China’s New Law and Comparisons to the US and Europe

November 19, 2026

Webinar

Conference

IPBC Asia 2026

November 17-19, 2026

Tokyo

Conference

NAPABA Convention 2026

November 12-14, 2026

Los Angeles

Conference

IAM Live: Trade Secret Strategy USA

November 10, 2026

San Jose

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP